May 17, 2017 21:16 pm UTC| Business
BOSTON, May 17, 2017 -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results from its Phase 1, multicenter,...
May 17, 2017 21:16 pm UTC| Business
NEW YORK, May 17, 2017 -- The following statement is being issued by Levi Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Neurotrope, Inc. (“Neurotrope”) (NASDAQ:NTRP)...
May 17, 2017 21:16 pm UTC| Business
NEW YORK, May 17, 2017 -- The following statement is being issued by Levi Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Neurotrope, Inc. (“Neurotrope”) (NASDAQ:NTRP)...
Mitel Reports Voting Results from 2017 Annual Meeting of Shareholders
May 17, 2017 21:10 pm UTC| Business
OTTAWA, May 17, 2017 -- Mitel® (Nasdaq:MITL) (TSX:MNW), a global leader in enterprise communications, announced at its Annual Meeting of Shareholders held on May 15, 2017 the election of 8 nominees proposed for its...
May 17, 2017 21:10 pm UTC| Business
Heidelberg, Germany, May 17, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that data for...
May 17, 2017 21:10 pm UTC| Business
Heidelberg, Germany, May 17, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that data for...
May 17, 2017 21:08 pm UTC| Business
-31% objective response rate for first stage of the Phase 2 melanoma cohort of ENCORE 601- -Enrollment ongoing in Stage 2, along with biomarker analysis- -ENCORE 601 now enrolling expanded cohorts of melanoma and NSCLC...